Skip to main content
Clinical Trials/NCT01867632
NCT01867632
Completed
Not Applicable

Does Acellular Dermal Matrix Reduce Fistula Rate in Primary Palatoplasty

Mirko S. Gilardino1 site in 1 country131 target enrollmentSeptember 2012
ConditionsCleft Palate

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cleft Palate
Sponsor
Mirko S. Gilardino
Enrollment
131
Locations
1
Primary Endpoint
Fistula Formation
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The goal of the present study is to definitely determine whether the use of acellular dermal matrix (ADM) during primary cleft palate repair decreases the rate of fistula formation. Although individual studies have described promising advantages to its use in cleft palate surgery, no consensus currently exists. Without concrete evidence, one must question the whether the increased cost, time and potential patient risk (human derived tissue) to patients justifies its use in primary cleft palate repair.

Detailed Description

There has been a change in the standard practice at the Montreal Children's Hospital where the senior author has shifted from selected application of ADM in certain cases to routine use of ADM in all cleft palate cases. This study is an observational study comparing a prospective cohort group receiving ADM routinely to a retrospective historical cohort group without routine use of ADM. Objectives of the study: Primary objectives: The primary objective of this study is to determine whether routine use of ADM would lower the incidence of palatal fistula in patients undergoing primary cleft palate repair. Secondary objectives: 1. Incidence of wound dehiscence 2. Incidence of wound infection 3. Hospital length of stay

Registry
clinicaltrials.gov
Start Date
September 2012
End Date
March 31, 2017
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Mirko S. Gilardino
Responsible Party
Sponsor Investigator
Principal Investigator

Mirko S. Gilardino

Director, Plastic Surgery Residency Program, Assistant Professor of Surgery

McGill University Health Centre/Research Institute of the McGill University Health Centre

Eligibility Criteria

Inclusion Criteria

  • Children diagnosed as having Veau class II to IV cleft palates undergoing Furlow palatoplasty with ADM between the ages of 3 months and 3 years will be included in this study.

Exclusion Criteria

  • Selection will be based on the parent's willingness to allow their child to participate in the study.
  • Children with diagnosed craniofacial syndromes will be excluded from the study due their higher than usual incidence of palatal fistulas.
  • Children with known wound healing defects, such as Ehler Danlos syndrome, Pseudoxanthoma Elasticum, will be excluded from the study due to their inherent collagen defects and consequently on the incidence of palatal fistulas.
  • Children with Veau class I cleft palates and those who will need/needed any surgical technique other then Furlow palatoplasty will be excluded from the study.

Outcomes

Primary Outcomes

Fistula Formation

Time Frame: Within 1 year of surgery

Number of patients who developed post palatoplasty fistula

Secondary Outcomes

  • Number of Participants With Wound Infection(Within 1 year of surgery)

Study Sites (1)

Loading locations...

Similar Trials